ML Drug Screening Using EEG Data for Neurological Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug screening processes are time-consuming and costly, involving extensive preclinical studies with animals and manual analysis of EEG data, which are prone to errors and inefficiencies, leading to high risks and resource consumption.
Innovation Solution
A machine learning-based method and system that processes EEG or EMG data from animal models to screen potential drug candidates by training a model on seizure-related signals, enabling the prediction of neurological adverse events and treatment efficacy, using a combination of data preprocessing, feature extraction, and classification with a convolutional neural network.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual analysis of EEG data is used to assess brain activity, then diagnostic accuracy can be maintained, but the process becomes time-consuming and error-prone
Solution Approach 1:
The patent replaces manual mechanical analysis of EEG data with an automated machine learning system that processes electroencephalogram and electromyogram signals to predict neurological adverse events and treatment efficacy, eliminating time-consuming manual review while maintaining diagnostic accuracy through algorithmic pattern recognition
Solution Approach 2:
The patent creates a computational model that replicates the diagnostic decision-making process by training machine learning algorithms on labeled EEG data from animal models, allowing the system to automatically copy and apply diagnostic patterns without requiring continuous manual expert analysis
2Reliability
If conventional drug screening processes are used with extensive preclinical studies, then safety evaluation can be thorough, but the process becomes costly and time-consuming
Solution Approach 1:
The patent performs preliminary safety evaluation by training machine learning models on EEG data from animal models before human clinical trials, allowing potential neurological adverse events to be identified in advance through automated analysis, thereby reducing the need for extensive lengthy preclinical studies while maintaining safety assessment quality
Solution Approach 2:
The patent changes the evaluation parameters by using machine learning predictions of neurological adverse events and treatment efficacy as primary screening criteria, replacing traditional lengthy observational studies with automated signal analysis that processes EEG and EMG data to provide rapid safety assessments
3Reliability
If two animal species are required for toxicological studies, then regulatory compliance is achieved, but the cost and time for drug development increase
Solution Approach 1:
The patent creates a universal machine learning model that can process and analyze EEG data from multiple animal species using the same algorithmic framework, allowing the system to maintain regulatory compliance through standardized analysis while reducing the need for species-specific studies and minimizing the total number of animals required
Data Source
AI summary
A drug screening method uses electroencephalogram (EEG) or electromyogram (EMG) data applied to a ML model. EEG or EMG data is measured from a first animal species during administration of a seizure-inducing agent. A ML model is trained with the first animal species EEG or EMG data as well as measured EEG orEMG from a second animal species such that the trained ML model is able to identify a neurological adverse event in the second animal species based on data from the first animal species. A potential drug candidate is screened by administering the potential drug candidate to the first animal species and measuring the EEG or EMG data of the first animal species during the potential drug candidate administration. The measured EEG or EMG data is applied to the ML model to determine whether there is the neurological adverse event associated with the drug candidate administration.